Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients
Status:
Withdrawn
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The primary objective is of this Phase 1 study is to evaluate the safety and tolerability of
daily, multiple, oral doses of CDX-6114 when administered to patients with PKU for 14 days.
The aim is to check if administration of daily, multiple, oral doses of CDX-6114 to patients
with PKU for 14 days shows a clinically acceptable safety and tolerability profile.